Cstone Pharmaceuticals, A Leading Biopharmaceutical Company Focused On The Research, Development, And Commercialization Of Innovative Immuno-Oncology Therapies And Precision Medicines, And Jiangsu Hengrui Pharmaceuticals Today Announced A Strategic Partnership And Exclusive Licensing Agreement On Anti-Ctla-4 Mab Cs1002 In The Greater China Region. This Strategic Partnership Marks Another Milestone In Cstone'S Mission To Introduce Innovative Oncology Therapies In China After The Commercial Launch Of Two First-In-Class Drugs This Year.Under The Terms Of The Agreement, Cstone Will Be Eligible For An Upfront Payment And Potential Milestone Payments Up To $200 Mn In Addition To Double-Digit Royalties. Hengrui Will Obtain The Exclusive Rights For Research, Development, Registration, Manufacturing, And Commercialization Of Anti-Ctla-4 Mab Cs1002 In Greater China. Cstone Will Retain The Rights To Develop And Commercialize Of Cs1002 Outside Of Greater China.Cytotoxic T Lymphocyte Associated Antigen 4 (Ctla-4) Is One Of The Few Clinically Validated Targets For Io Combination Therapies. There Is Only One Anti-Ctla-4 Monoclonal Antibody Approved Globally, And It Is Also Approved In China. According To Evaluatepharma, The Annual Global Revenue Of The Product In 2020 Was Approximately $1.69 Billion. Cs1002 Is An Investigational Anti-Ctla-4 Monoclonal Antibody Being Developed By Cstone Currently In Clinical Development. Results From The Ongoing Ph1A/1B Study Showed That Differentiated Dosing Schedules Of Cs1002 In Combination With Cs1003 (Anti-Pd-1) Were Well-Tolerated And Demonstrated Very Encouraging Efficacy In Anti-Pd-(L)1-Refractory Melanoma, Anti-Pd-(L)1-Refractory Hepatocellular Carcinoma, And Anti-Pd-(L)1-Na
